Paper2289481
The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy.
Sander JW and 4 others. Epilepsy Res, 1990. Cited by 60 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Papers, record 2289481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2289481
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Epilepsy | Major topic |
| Triazines | Major topic |
| Anticonvulsants | |
| Dose-Response Relationship, Drug | |
| Female | |
| Humans | |
| Lamotrigine | |
| Male | |
| Osmolar Concentration | |
| Time Factors |
Source PubMed
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35,483,204 | Movement disorders associated with antiseizure medications: A systematic review. | Epilepsy Behav | 2022 | https://conductscience.org/library/papers/35483204 | PubMed |
| 27,348,062 | Decision analysis of intracranial monitoring in non-lesional epilepsy. | Seizure | 2016 | https://conductscience.org/library/papers/27348062 | PubMed |
| 25,391,707 | Drug-induced cerebellar ataxia: a systematic review. | CNS Drugs | 2014 | https://conductscience.org/library/papers/25391707 | PubMed |
| 18,370,548 | Lamotrigine in multihandicapped therapy-resistant epileptic patients. | Clin Drug Investig | 1998 | https://conductscience.org/library/papers/18370548 | PubMed |
| 9,862,243 | Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. | Br J Clin Pharmacol | 1998 | https://conductscience.org/library/papers/9862243 | PubMed |
| 9,565,739 | Safety review of adult clinical trial experience with lamotrigine. | Drug Saf | 1998 | https://conductscience.org/library/papers/9565739 | PubMed |
| 8,916,751 | Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome. | BMJ | 1996 | https://conductscience.org/library/papers/8916751 | PubMed |
| 8,891,461 | Drug treatment of epilepsy in the 1990s. Achievements and new developments. | Drugs | 1996 | https://conductscience.org/library/papers/8891461 | PubMed |
| 8,536,554 | Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. | Drugs | 1995 | https://conductscience.org/library/papers/8536554 | PubMed |
| 8,240,723 | Antiepileptic drugs. A review of clinically significant drug interactions. | Drug Saf | 1993 | https://conductscience.org/library/papers/8240723 | PubMed |
| 7,917,080 | Newer antiepileptic drugs. Towards an improved risk-benefit ratio. | Drug Saf | 1994 | https://conductscience.org/library/papers/7917080 | PubMed |
| 7,691,504 | Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. | Drugs | 1993 | https://conductscience.org/library/papers/7691504 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2289481
GET https://conductscience.org/api/papers/v1/2289481/authors